IOM on cancer trials
This article was originally published in The Gray Sheet
Executive Summary
The National Cancer Institute should coordinate with FDA on the review and oversight of new device and drug trials "to eliminate iterative review steps" and FDA should follow through on plans to establish a coordinated cancer program to avoid conflicting review requirements for cancer combination products, the Institute of Medicine recommends in its April 15 1report on the U.S. cancer clinical trial system. IOM also urges enhanced use of biomarkers in clinical trial protocols. The report was developed at the request of NCI to outline an approach to reforming the cancer clinical trials infrastructure. It includes four broad-based recommendations: to improve the speed and efficiency of the design, launch and conduct of trials; to better incorporate innovative science into trials; to improve the process for prioritizing and funding trials; and to increase patient and physician participation
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.